Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study

Introduction Current international guidelines recommend non-vitamin K oral anticoagulants (NOACs) for stroke prevention among patients with non-valvular atrial fibrillation (AF) at significant ischaemic stroke risk given the superior safety and comparable efficacy of NOACs over warfarin. Nonetheless...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ open 2020-09, Vol.10 (9), p.e038194-e038194, Article 038194
Hauptverfasser:	Zhou, Mi, Chan, Esther W., Hai, Jo Jo, Wong, Chun Ka, Lau, Yuk Ming, Huang, Duo, Lam, Cheung Chi, Tam, Chor Cheung Frankie, Wong, Yiu Tung Anthony, Yung, See Yue Arthur, Chan, Ki Wan Kelvin, Feng, Yingqing, Tan, Ning, Chen, Ji-yan, Yung, Chi Yui, Lee, Kwok Lun, Choi, Chun Wai, Lam, Ho, Ng, Andrew, Fan, Katherine, Jim, Man Hong, Yiu, Kai Hang, Yan, Bryan P., Siu, Chung Wah
Format:	Artikel
Sprache:	eng
Schlagworte:	Ablation Administration, Oral Adolescent Adult Anemia Anticoagulants Anticoagulants - adverse effects Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Blood pressure Brain Ischemia - drug therapy Cardiac arrhythmia Cardiovascular disease Cardiovascular Medicine Clinical medicine Clinical trials Creatinine Dabigatran - adverse effects Disease prevention Drug dosages Embolisms Endocarditis General & Internal Medicine Glycoproteins Hemoglobin Hong Kong Humans Hypertension Informed consent Ischemia Life expectancy Life Sciences & Biomedicine Medicine, General & Internal Mitral Valve Stenosis - complications Prospective Studies Prostheses Randomized Controlled Trials as Topic Science & Technology Stroke Stroke - drug therapy Stroke - etiology Stroke - prevention & control Thrombocytopenia Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!